Join DS2 at Obesity Science & Innovation USA 2026
DS2 will be at Obesity Science & Innovation USA in Boston on September 23 and 24, in the sessions across both days and meeting customers and partners around them. Put a time in with us.
Let's Connect in Boston
Obesity Science & Innovation brings together more than 150 experts in obesity and metabolic health, with external innovation and search and evaluation leads from Eli Lilly, Novo Nordisk, Zealand Pharma and AstraZeneca in the room alongside the biotech CEOs and CSOs building the next wave of therapeutics. Cardiometabolic programs generate a lot of samples across a lot of visits, and we provide industry-leading solutions across the entire connected sample supply chain. Collection kits built for repeat metabolic panels, mobile phlebotomy that keeps participants in a study without a site visit, cold chain for biomarker and PK samples, biostorage for long-term follow-up, and results returning cleanly into your systems. We'd love to talk through what your protocol asks of participants and how we would support it.
We often find during these events that the diary fills up quickly. Use the form and we'll block a time for you to meet our team while availability lasts.
Why Attend Obesity Science & Innovation USA 2026?
Informa Connect describes the event as “the premier annual conference bringing together over 150 leading experts in obesity and metabolic health to shape the future of emerging obesity therapeutics,” under the theme “From Innovation to Impact.”
What the programme covers: The published focus is on incretin-based therapeutics including GLP-1 and combination agonists, RNA-based approaches to obesity, adipose-targeted therapies, muscle preservation, GLP-1 applications beyond obesity, and an Innovation Spotlight covering emerging modalities.
Deliberately partnering-shaped: Day one opens with back-to-back keynote panels on redefining healthy weight loss and on what pharma and investors need to see before they commit, and the base ticket includes access to partneringONE along with the joint exhibition hall shared with RNA Leaders USA.
Where the commercial conversation sits: Day two closes with a plenary on pricing and reimbursement in obesity therapeutics, which is where much of the commercial conversation in this field currently sits.
Why Meet with DS2?
Metabolic and cardiometabolic studies ask a lot of participants. Repeat blood draws, long follow-up windows and endpoints that depend on samples arriving in the right condition, visit after visit. DS2 builds and runs the supply chain underneath that, including at-home collection where the protocol allows it. What we do:
- Diagnostic and specimen collection kit design, assembly and fulfillment
- Kit-to-patient and direct-to-patient distribution
- Medical courier services, including STAT and next-flight-out specimen transport
- Cold chain and temperature-controlled logistics, with the documentation to prove the range held
- Biostorage and biorepository services
- Mobile phlebotomy and specimen collection
- LIS, LIMS and EMR integration, including HL7 and FHIR
- Chain of custody and compliance documentation
Kit design for repeat metabolic panels, mobile phlebotomy, courier and cold chain, biostorage for long-term follow-up, and the integration that puts results back where your team needs them. We're looking forward to getting into it in Boston.
Speaking Faculty
A selection from the 35 speakers published for 2026.
Robrecht Thoonen
Eli Lilly
Senior Director, External Innovation, Diabetes, Obesity and Cardiometabolic
Laura Holberger
Novo Nordisk
Associate Director, R&D External Innovation Partners
Tari Suprapto
Zealand Pharma
Vice President, Search and Evaluation
Myung Shin
Zealand Pharma
Vice President, Biology, Discovery Research
Sonali Malhorta Singh
AstraZeneca
Clinical Development Medical Director
Jeremie Boucher
Evotec
Senior Vice President, Head of Metabolic Disease
Mimoun Ayoub
CordenPharma International
Senior Vice President, Global Head of Peptide and Oligonucleotide Platforms
Philip Larsen
Antag Therapeutics
Chief Executive Officer
Mitchell Steiner
VERU
President and Chief Executive Officer
Laurent Audoly
Prive Bio
Chief Executive Officer
Paul Edison
UCL
Professor of Neuroscience
Anders Näär
UC Berkeley
Professor of Metabolic Biology
The full speaker list is on the official speakers page.
The Agenda, Day by Day
Times below are as published by Informa Connect. The full session list is on the official agenda page.
Day One · Wednesday, September 23, 2026
Morning registration and breakfast
Welcome and opening chair remarks
Kaitlin Dailey, Senior Conference Producer, Informa Connect
Keynote panel: Redefining Healthy Weight Loss, Innovations, Challenges and Future Opportunities
Raj Reddy, Canary Cure; Steffen-Sebastian Bolz, Aphaia Pharma; Philip Larsen, Antag Therapeutics; Luba Greenwood, Mwyngil Therapeutics
Keynote panel: Partnerships In Focus, Essential Pharma and Investor Must Haves
Robrecht Thoonen, Eli Lilly; Laura Holberger, Novo Nordisk; Tari Suprapto, Zealand Pharma; Geoff MacKay, Fable Therapeutics
Morning refreshment break
Achieving Excellence in Clinical Trial Site Performance for Cardiometabolic Research
Kate Tilley, Vice President, Business Development, Nucleus Network
siRNA therapeutics for obesity and metabolic disease
Raj Reddy, Canary Cure; Janine Sengstack, Junevity; Lucas BonDurrant, Alnylam
Lunch break
Target discovery, amylin pharmacology and pediatric obesity
Jeremie Boucher, Evotec; Myung Shin, Zealand Pharma; Lloyd Tran, Biomed Industries; Sonali Malhorta Singh, AstraZeneca
Afternoon refreshment break
Energy expenditure and brown adipose approaches
Olivier Boss, Energesis Pharmaceuticals; Anton Petrov, Mitotech; Anders Näär, UC Berkeley
Networking drinks reception
Day Two · Thursday, September 24, 2026
Biotech Week Boston Fun Run
Morning registration, breakfast and Innovation Spotlight chair
Innovation Spotlight presentations
Laurent Audoly, Prive Bio; Peng Leong, BioAge Labs; Steffen-Sebastian Bolz, Aphaia Pharma; Joanne Hsieh, Gordian Biotechnology
Morning refreshment break
Leveraging Site-Specific Modifications to Create Next Generation GLP-1 Peptides
Saleha Patel, Head of Pipeline and Commercialization Strategy, Constructive Bio
In focus: muscle-preserving therapeutics
Mitchell Steiner, VERU; Tom Hsu, Ibio
Lunch break
Preserving lean mass in the GLP-1 era
Stuart Peltz and Timothy Dyer, NovMetaPharma; Dave Baker, Fable Therapeutics
GLP-1s beyond obesity
Paul Edison, UCL; Rana Assaly, Cardiomedex; Francois Briand, Physiogenex; David Pass, Altrix Bio
Afternoon refreshment break
Closing keynote plenary: Breaking Barriers, Addressing Pricing and Reimbursement Challenges in Obesity Therapeutics
Mimoun Ayoub, CordenPharma International; Laurent Audoly, Prive Bio; Joseph Zucchi, New England Obesity Society
Close of Obesity Science & Innovation 2026
Biotech Week Boston Festival Party at the Museum of Science
Useful Obesity Science & Innovation Resources
The official event page.
AgendaThe full session list for both days.
SpeakersThe published faculty.
Add on: RNA LeadersThe $200 upgrade into RNA Leaders USA.
PartneringHow partneringONE works at this event.
VenueGetting to the Hynes.
Book Your HotelThe official room block.
Hotel Fraud AdvisoryRead before booking through a third party.
Register NowPass types and pricing.
Obesity Science & Innovation USA 2026 FAQ
General
Fees & registration
Venue & travel
See You in Boston
Boston, September 23 and 24. Tell us what your protocol asks of participants and we'll set aside time to talk through how we would run the sample side of it.